Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... myelodysplastic syndrome patients treated with azacitidine (AZA) remain largely unknown. Two hundred eighty-two ...

    Research Article last updated 07/28/2014 - 8:53am.

  2. 5'-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3.

    ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Personalized medicine for MDS

    ... accordingly. -Hypomethylating agents, such as azacitidine and decitabine , are standard care for older patients ... MDS who are not candidates for stem cell transplant.  Azacitidine in particular has been shown to have a survival advantage compared ...

    Research Review last updated 05/02/2016 - 9:44am.

  4. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently ... myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is ...

    Research Article last updated 11/19/2015 - 8:32am.

  5. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents

    ... myelodysplastic syndrome (MDS) patients in whom azacitidine was the only treatment to demonstrate an overall survival ...

    Research Article last updated 09/29/2015 - 2:12pm.

  6. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... describing common adverse events (AEs) associated with azacitidine and methods to manage them. METHODS: In the Cancer ... (FAB) subtype of MDS were randomized to azacitidine or best supportive care (BSC). After 56 d, patients ... to BSC with disease progression could cross over to receive azacitidine. In the AZA-001 study, patients with higher-risk MDS (FAB-defined ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

    ... Hypomethylating agents (HMA), such as 5- azacitidine or decitabine , are currently used to treat patients ...

    Research Article last updated 05/26/2015 - 12:53pm.

  8. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... for its treatment: lenalidomide , 5- azacitidine , and decitabine . These therapies can be effective in ... and reduction in bone marrow blasts . 5-azacitidine has also been shown to improve overall survival. However, there ...

    Research Article last updated 05/26/2015 - 12:13pm.

  9. An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

    ... to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with higher-risk myelodysplastic syndromes, ...

    Clinical Trial last updated 04/28/2016 - 1:58pm.

  10. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... efficacy of disease-modifying therapies, such as azacitidine or lenalidomide . The recombinant human ...

    Research Article last updated 03/04/2015 - 10:20am.